Ignite Creation Date:
2024-05-06 @ 3:03 AM
Last Modification Date:
2024-10-26 @ 11:27 AM
Study NCT ID:
NCT02193360
Status:
UNKNOWN
Last Update Posted:
2016-08-24
First Post:
2014-07-11
Brief Title:
Pilot Study of FFP104 Dose Escalation in PBC Subjects
Sponsor:
Fast Forward Pharmaceuticals
Organization:
Fast Forward Pharmaceuticals
Study Overview
Official Title:
A Phase III Open Label Multicenter Pilot Dose Escalation Study to Evaluate the Safety Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis PBC
Status:
UNKNOWN
Status Verified Date:
2016-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the initial safety tolerability and pharmacodynamics of the CD40-antagonist Mab FFP104 in subjects with PBC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-001638-27 | EUDRACT_NUMBER | None | None |